Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
4 pending office actions • 2 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
Natco Pharma Limited holds 4 pending office actions in the Biotechnology & Pharmaceuticals technology area. These matters are assigned to 4 distinct examiners and 2 distinct art units. STEINKE, SEAN JAMES is the busiest examiner with 1 pending office action. With 4 examiners for the pending actions, the company is dealing with a different individual for every case.
The concentration in 2 distinct art units suggests the pharmaceutical filings are grouped into two specific technical areas. This requires managing multiple examiner relationships within a relatively narrow set of art unit guidelines. Practitioners should be prepared for different examination styles despite the limited number of art units. The biotechnology and pharmaceuticals focus is split between these 2 distinct art units, requiring a strategy that addresses both specialized groups. STEINKE, SEAN JAMES is 1 of the examiners currently reviewing the company's applications. This structure ensures that the company's patent outcomes are determined by multiple perspectives.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (25%) |
| Multi-statute (no §101) | 3 (75%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| STEINKE, SEAN JAMES | 1 | 12.5% | +42.9% |
| JOHNSON, CHRISTOPHER LINDSAY | 1 | 46.9% | +81.0% |
| MOORE, SUSANNA | 1 | 68.1% | +31.6% |
| CORNET, JEAN P | 1 | 42.1% | +47.5% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18853465 | STABLE PHARMACEUTICAL COMPOSITIONS COMPRISING ERDAFITINIB | STEINKE, SEAN JAMES | — |
| 18712871 | AN IMPROVED PROCESS FOR THE PREPARATION OF CRYSTALLINE FORM-A OF CYANTRANILIPROLE | JOHNSON, CHRISTOPHER LINDSAY | — |
| 18692678 | AN IMPROVED PROCESS FOR THE PREPARATION OF RUXOLITINIB PHOSPHATE | MOORE, SUSANNA | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18853465 | STABLE PHARMACEUTICAL COMPOSITIONS COMPRISING ERDAFITINIB | STEINKE, SEAN JAMES | — |
| 18712871 | AN IMPROVED PROCESS FOR THE PREPARATION OF CRYSTALLINE FORM-A OF CYANTRANILIPROLE | JOHNSON, CHRISTOPHER LINDSAY | — |
| 18692678 | AN IMPROVED PROCESS FOR THE PREPARATION OF RUXOLITINIB PHOSPHATE | MOORE, SUSANNA | — |
| 18686936 | NOVEL CRYSTALLINE POLYMORPH OF LURBINECTEDIN AND IMPROVED PROCESS FOR THE PREPARATION OF LURBINECTEDIN | CORNET, JEAN P | — |
| Art Unit | Apps |
|---|---|
| 1624 | 1 |
| 1628 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18853465 | STABLE PHARMACEUTICAL COMPOSITIONS COMPRISING ERDAFITINIB | STEINKE, SEAN JAMES | — | §103§112 | Non-Final OA | — | Pending | Oct 02, 2024 |
| 18712871 | AN IMPROVED PROCESS FOR THE PREPARATION OF CRYSTALLINE FORM-A OF CYANTRANILIPROLE | JOHNSON, CHRISTOPHER LINDSAY | — | §102§112 | Non-Final OA | — | Pending | May 23, 2024 |
| 18692678 | AN IMPROVED PROCESS FOR THE PREPARATION OF RUXOLITINIB PHOSPHATE | MOORE, SUSANNA | 1624 | §103§112 | Non-Final OA | — | Pending | Mar 15, 2024 |
| 18686936 | NOVEL CRYSTALLINE POLYMORPH OF LURBINECTEDIN AND IMPROVED PROCESS FOR THE PREPARATION OF LURBINECTEDIN | CORNET, JEAN P | 1628 | §112 | Non-Final OA | — | Pending | Feb 27, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial